Virtus ETF Advisers LLC Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Virtus ETF Advisers LLC cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 42.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,393 shares of the biopharmaceutical company's stock after selling 8,258 shares during the quarter. Virtus ETF Advisers LLC's holdings in TG Therapeutics were worth $343,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Quadrant Capital Group LLC grew its stake in shares of TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after buying an additional 975 shares in the last quarter. Blue Trust Inc. boosted its holdings in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the period. Smartleaf Asset Management LLC boosted its holdings in TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 1,594 shares during the period. Jones Financial Companies Lllp increased its stake in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter worth about $75,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TGTX shares. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Stock Down 0.3 %

NASDAQ TGTX traded down $0.14 on Thursday, hitting $45.37. 2,545,060 shares of the stock were exchanged, compared to its average volume of 2,701,508. TG Therapeutics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The company has a 50-day moving average price of $37.95 and a 200-day moving average price of $32.90. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market cap of $7.20 billion, a PE ratio of -453.65 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.